Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 2/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.59 |
| ▸ | BCR | P11274 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 6/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.59 |
| ▸ | NHERF1 | O14745 | 3/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735975 | 0.90 | SRC (0.62) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL7208136 | 0.84 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL29475123 | 0.84 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL14845689 | 0.84 | TP53 (1.00) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL2735818 | 0.84 | NPC1 (0.71) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL27385788 | 0.84 | NPC1 (0.71) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL31058769 | 0.84 | NHERF1 (0.78) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL16465542 | 0.83 | NPC1 (0.97) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL30702259 | 0.82 | TP53 (0.54) | NPC1RAB9ALMNASMN1; SMN2TP53 | |
| SCHEMBL30702268 | 0.82 | TP53 (0.51) | NPC1RAB9ALMNASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-7901894-B2 | Kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-03-08 | — | — | US | disclosed |
| US-7901894-B2 | Kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-03-08 | — | — | US | disclosed |
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-02-03 | — | — | US | disclosed |
| US-7838542-B2 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838542-B2 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-7772216-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772216-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | OAKTREE FUND ADMINISTRATION, LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | OAKTREE FUND ADMINISTRATION, LLC | 2008-01-03 | — | — | US | disclosed |
| EP-0624575-A1 | Substituted indoles and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | PTPN5, PTPN2, PTPN4 | NPC1 3928/4885RAB9A 3134/4885LMNA 4738/4885 |
| US-20080004241-A1 | 2-carboxamide substituted indoles; osteoporosis, hepatitis B, ophthalmic disease, diabetes, atherosclerosis, obesity, chronic neuropathic pain, stroke; protein tyrosine kinase (PTK) inhibitors; 5-fluoro-3-phenylindole-2-carboxamides | PTK2B, GRK2, FRK | NPC1 696/4885RAB9A 2336/4885LMNA 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.